Agios Pharma (AGIO) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Agios Pharma (AGIO) Misses Q3 EPS by 1c

Agios Reports Business Highlights and Third Quarter 2019 Financial Results

October 31, 2019 7:00 AM EDT

TIBSOVO® Net Revenue of $17.4 Million; 27% Growth from Q2 2019

Reported Positive Phase 3 ClarIDHy Results for TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission Planned by Year-End

Presented Data from Single Agent Dose-Escalaton Arm of the Phase 1 Study of AG-270 in MTAP Deleted Tumors; Combination Arms with Taxanes in Non-Small Cell Lung Cancer and Pancreatic Cancer Initiated

Published Updated DRIVE PK Data for Mitapivat in PK Deficiency in New England Journal of Medicine; Updated Data from Extension Phase to be Presented at American Society of Hematology Annual Meeting

... More